Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript

SA Transcripts 161.76K Followers Follow Taysha Gene Therapies, Inc. ( TSHA ) Q2 2026 Earnings Call August 11, 2026 4:30 PM EDT Company Participants Hayleigh Collins - Director of Corporate Communications & Investor Relations Sean Nolan - CEO & Chairman Sukumar Nagendran - President, Head of Research & Development and Director Kamran Alam - CFO & Corporate Secretary Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Tazeen Ahmad - BofA Securities, Research Division Maurice Raycroft - Jefferies LLC, Research Division Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division Angela Qian - Canaccord Genuity Corp., Research Division Evan Seigerman - BMO Capital Markets Equity Research Presentation Operator Hello, and welcome to the Taysha Gene Therapies Second Quarter 2026 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. It is now my pleasure to introduce Vice President of Corporate Communications and Investor Relations, Hayleigh Collins. Hayleigh Collins Director of Corporate Communications & Investor Relations Thank you. Good afternoon, and welcome to Taysha's second quarter 2026 financial results and corporate update conference call. Earlier today, Taysha issued a press release announcing financial results for the quarter ended June 30, 2026. A copy of this press release is available on the company's website and through our SEC filings. Joining me on today's call are Sean Nolan, Taysha's Chief Executive Officer, Sukumar Nagendran, President and Head of R&D; and Kamran Alam, Chief Financial Officer. We will hold a question-and-answer session following our prepared remarks. On today's call, we will be making forward-looking statements, including statements concerning the potential of TSHA-102, including the reproducibility and durability of any favorable results initially seen in patients dosed to date in clinical trials, including with respect to functional milestones, to positively impact quality of life and alter the